The safety and clinical benefit of budesonide/formoterol pressurized metered-dose inhaler versus budesonide alone in children

Allergy and Asthma Proceedings

Volumn 31, Issue 1, 2010, Pages 26-39

  Berger, William E ^a   Leflein, Jeffrey G ^b   Geller, David E ^c   Parasuraman, Bhash ^d   Miller, Christopher J ^d   O'Brien, Christopher D ^d   O'Dowd, Liza ^d  

^a Allergy & Asthma Associates of Southern California   (United States)

^b Allergy and Immunology Associates of Ann Arbor PC   (United States)

^c NEMOURS CHILDREN S HOSPITAL   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Asthma; Budesonide; Children; Efficacy; Formoterol; Inhaled corticosteroid; Pediatric; Pressurized metered dose inhaler; Safety

Indexed keywords

BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; GLUCOSE; HYDROCORTISONE; POTASSIUM; SYMBICORT INHALATION AEROSOL; UNCLASSIFIED DRUG;

ARTICLE; CANDIDIASIS; CAREGIVER; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; COUGHING; CREATININE URINE LEVEL; DAILY LIFE ACTIVITY; DIARRHEA; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAM; FATIGUE; FEMALE; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEART RATE; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYDROCORTISONE URINE LEVEL; HYPERGLYCEMIA; HYPOKALEMIA; INSOMNIA; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MODERATE PERSISTENT ASTHMA; MULTICENTER STUDY; POTASSIUM BLOOD LEVEL; POWDER INHALER; PRESCHOOL CHILD; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; TACHYCARDIA; THERAPY EFFECT; THORAX PAIN; THRUSH; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN;

ADMINISTRATION, INHALATION; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; CHILD; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; ETHANOLAMINES; FEMALE; HUMANS; MALE; METERED DOSE INHALERS; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 76149124862     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2010.31.3301     Document Type: Article

References (38)

1. National Asthma Education and Prevention Program. Expert panel report 3: Guidelines for the diagnosis and management of asthma. Full Report 2007. Available online at www.nhlbi. nih.gov/guidelines/asthma/asthgdln.pdf; last accessed September 5, 2007.
2. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Updated 2008. Available online at www.ginasthma.org/Guidelineitem.asp??l1=2&l2=1&intId=60; last accessed February 9, 2009.
3. Ind PW, Dal Negro R, Colman NC, et al. Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma. Respir Med 97:555-562, 2003.
4. Lalloo UG, Malolepszy J, Kozma D, et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest 123:1480 -1487, 2003.
5. Pauwels RA, Löfdahl C-G, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 337:1405-1411, 1997.
6. Kramer JM. Balancing the benefits and risks of inhaled long-acting beta-agonists-The influence of values. N Engl J Med 360:1592-1595, 2009.
7. U.S. Food and Drug Administration. Summary Minutes of the Joint Pulmonary-Allergy Drugs Advisory Committee (PADAC), Drug Safety and Risk Management Advisory Committee (DSaRM), and Pediatric Advisory Committee (PAC), December 10-11, 2008. Available online at www.fda.gov/ohrms/dockets/ac/08/ minutes/2008-4398m1-final.pdf; last accessed February 9, 2009.
8. Ericson A, and Källén B. Use of drugs during pregnancy - Unique Swedish registration method that can be improved. Medical Products Agency - Sweden 1:8 -11, 1999.
9. Norjavaara E, and de Verdier MG. Normal pregnancy outcomes in a population-based study including 2968 pregnant women exposed to budesonide. J Allergy Clin Immunol 111:736 -742, 2003.
10. Leflein JG, Gawchik SM, Galant SP, et al. Safety of budesonide inhalation suspension (Pulmicort Respules) after up to 52 weeks of treatment in infants and young children with persistent asthma. Allergy Asthma Proc 22:359 -366, 2001.
11. Shapiro G, Bronsky EA, LaForce CF, et al. Dose-related efficacy of budesonide administered via a dry powder inhaler in the treatment of children with moderate to severe persistent asthma. J Pediatr 132:976 -982, 1998.
12. Szefler SJ, Lyzell E, Fitzpatrick S, et al. Safety profile of budesonide inhalation suspension in the pediatric population: Worldwide experience. Ann Allergy Asthma Immunol 93:83-90, 2004.
13. Berger WE, Qaqundah PY, Blake K, et al. Safety of budesonide inhalation suspension in infants aged six to twelve months with mild to moderate persistent asthma or recurrent wheeze. J Pediatr 146:91-95, 2005.
14. Leflein JG, Szefler SJ, Murphy KR, et al. Nebulized budesonide inhalation suspension compared with cromolyn sodium nebulizer solution for asthma in young children: Results of a randomized outcomes trial. Pediatrics 109:866-872, 2002.
15. Scott MB, and Skoner DP. Short-term and long-term safety of budesonide inhalation suspension in infants and young children with persistent asthma. J Allergy Clin Immunol 104:S200-S209, 1999.
16. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 343:1054 -1063, 2000.
17. Agertoft L, and Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 343:1064 -1069, 2000.
18. Chipps BE. Inhaled corticosteroid therapy for patients with persistent asthma: Learnings from studies of inhaled budesonide. Allergy Asthma Proc 30:217-228, 2009.
19. Corren J, Korenblat PE, Miller CJ, et al. Twelve-week randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adults and adolescents with asthma. Clin Ther 29:823- 843, 2007.
20. Noonan M, Rosenwasser LJ, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma. A randomised clinical trial. Drugs 66:2235-2254, 2006.
21. Morice AH, Peterson S, Beckman O, et al. Efficacy and safety of a new pressurised metered-dose inhaler formulation of budesonide/formoterol in children with asthma: A superiority and therapeutic equivalence study. Pulm Pharmacol Ther 21:152-159, 2008.
22. Peters SP, Prenner BM, Mezzanotte WS, et al. Long-term safety and asthma control with budesonide/formoterol versus budesonide pressurized metered-dose inhaler in asthma patients. Allergy Asthma Proc 29:499 -516, 2008.
23. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am Rev Respir Dis 136:225-244, 1987.
24. Juniper EF, Guyatt GH, Feeny DH, et al. Measuring quality of life in children with asthma. Qual Life Res 5:35- 46, 1996.
25. Juniper EF, Guyatt GH, Feeny DH, et al. Measuring quality of life in the parents of children with asthma. Qual Life Res 5:27-34, 1996.
26. Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 47:81- 87, 1994.
27. Bacharier LB, Raissy HH, Wilson L, et al. Long-term effect of budesonide on hypothalamic-pituitary-adrenal axis function in children with mild to moderate asthma. Pediatrics 113:1693-1699, 2004.
28. Tronde A, Gillen M, Borgström L, et al. Pharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPD. J Clin Pharmacol 48:1300 -1308, 2008.
29. Tal A, Simon G, Vermeulen JH, et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr Pulmonol 34:342-350, 2002.
30. Rosenhall L, Heinig JH, Lindqvist A, et al. Budesonide/formoterol (Symbicort) is well tolerated and effective in patients with moderate persistent asthma. Int J Clin Pract 56: 427- 433, 2002.
31. Rosenhall L, Elvstrand A, Tilling B, et al. One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma. Respir Med 97:702-708, 2003.
32. Ankerst J, Persson G, and Weibull E. Tolerability of a high dose of budesonide/formoterol in a single inhaler in patients with asthma. Pulm Pharmacol Ther 16:147-151, 2003.
33. Berger WE, Bleecker ER, O'Dowd L, et al. Efficacy and safety of once- or twice-daily budesonide/formoterol pressurized metered-dose inhaler: Randomized controlled trial comparing once- and twice-daily dosing in patients with asthma. Allergy Asthma Proc 31:73- 82, 2010.
34. 75%) in inhaled corticosteroid (ICS)-dependent patients with mild to moderate or moderate to severe persistent asthma receiving budesonide/ formoterol pressurized metered-dose inhaler (BUD/FM pMDI). J Allergy Clin Immunol 123:S158, 2009.
35. Chervinsky P, Baker J, Bensch G, et al. Patient-reported outcomes in adults with moderate to severe asthma after use of budesonide and formoterol administered via 1 pressurized metered-dose inhaler. Ann Allergy Asthma Immunol 101:463-473, 2008.
36. Murphy K, Nelson H, Parasuraman B, et al. The effect of budesonide and formoterol in one pressurized metered-dose inhaler on patient-reported outcomes in adults with mild-to-moderate persistent asthma. Curr Med Res Opin 24:879-894, 2008.
37. Everden P, Campbell M, Harnden C, et al; FACT study group. Eformoterol Turbohaler compared with salmeterol by dry powder inhaler in asthmatic children not controlled on inhaled corticosteroids. Pediatr Allergy Immunol 15:40-47, 2004.
38. Jönsson B, Berggren F, Svensson K, et al. An economic evaluation of combination treatment with budesonide and formoterol in patients with mild-to-moderate persistent asthma. Respir Med 98:1146-1154, 2004.